1. Herzog, C.E. Overview of sarcomas in the adolescent and young adult population. J. Pediatr. Hematol. Oncol. 2005, 27, 215–218. [CrossRef]
2. Ferrari, A.; Dirksen, U.; Bielack, S. Sarcomas of Soft Tissue and Bone. Prog. Tumor Res. 2016, 43, 128–141.
3. Ladanyi, M.; Antonescu, C.R.; Leung, D.H.; Woodruff, J.M.; Kawai, A.; Healey, J.H.; Brennan, M.F.; Bridge, J.A.; Neff, J.R.; Barr, F.G.; et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: A multi-institutional retrospective study of 243 patients. Cancer Res. 2002, 62, 135–140.
4. Al-Hussaini, H.; Hogg, D.; Blackstein, M.E.; O’Sullivan, B.; Catton, C.N.; Chung, P.W.; Griffin, A.M.; Hodgson, D.; Hopyan, S.; Kandel, R.; et al. Clinical features, treatment, and outcome in 102 adult and pediatric patients with localized high-grade synovial sarcoma. Sarcoma 2011, 2011, 231789. [CrossRef] [PubMed]
5. Outani, H.; Kakunaga, S.; Hamada, K.; Takenaka, S.; Imura, Y.; Nagata, S.; Tanaka, T.; Tamiya, H.; Oshima, K.; Naka, N.; et al. Favorable outcomes of localized synovial sarcoma patients with a high utilization rate of neoadjuvant and/or adjuvant chemotherapy. Mol. Clin. Oncol. 2019, 11, 151–156. [CrossRef] [PubMed]
6. Sultan, I.; Rodriguez-Galindo, C.; Saab, R.; Yasir, S.; Casanova, M.; Ferrari, A. Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: An analysis of 1268 patients. Cancer 2009, 115, 3537–3547. [CrossRef] [PubMed]
7. Clark, J.; Rocques, P.J.; Crew, A.J.; Gill, S.; Shipley, J.; Chan, A.M.; Gusterson, B.A.; Cooper, C.S. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat. Genet. 1994, 7, 502–508. [CrossRef] [PubMed]
8. Panagopoulos, I.; Mertens, F.; Isaksson, M.; Limon, J.; Gustafson, P.; Skytting, B.; Akerman, M.; Sciot, R.; Dal Cin, P.; Samson, I.; et al. Clinical impact of molecular and cytogenetic findings in synovial sarcoma. Genes Chromosomes Cancer 2001, 31, 362–372. [CrossRef]
9. Carmody Soni, E.E.; Schlottman, S.; Erkizan, H.V.; Uren, A.; Toretsky, J.A. Loss of SS18-SSX1 inhibits viability and induces apoptosis in synovial sarcoma. Clin. Orthop. Relat. Res. 2014, 472, 874–882. [CrossRef]
10. McBride, M.J.; Pulice, J.L.; Beird, H.C.; Ingram, D.R.; D’Avino, A.R.; Shern, J.F.; Charville, G.W.; Hornick, J.L.; Nakayama, R.T.; Garcia-Rivera, E.M.; et al. The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma. Cancer Cell 2018, 33, 1128–1141. [CrossRef]
11. Banito, A.; Li, X.; Laporte, A.N.; Roe, J.S.; Sanchez-Vega, F.; Huang, C.H.; Dancsok, A.R.; Hatzi, K.; Chen, C.C.; Tschaharganeh, D.F.; et al. The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma. Cancer Cell 2018, 34, 346–348. [CrossRef] [PubMed]
12. Anastas, J.N.; Moon, R.T. WNT signalling pathways as therapeutic targets in cancer. Nat. Rev. Cancer 2013, 13, 11–26. [CrossRef] [PubMed]
13. Sato, H.; Hasegawa, T.; Kanai, Y.; Tsutsumi, Y.; Osamura, Y.; Abe, Y.; Sakai, H.; Hirohashi, S. Expression of cadherins and their undercoat proteins (α-, β-, and γ-catenins and p120) and accumulation of β-catenin with no gene mutations in synovial sarcoma. Virchows Arch. 2001, 438, 23–30. [PubMed]
14. Trautmann, M.; Sievers, E.; Aretz, S.; Kindler, D.; Michels, S.; Friedrichs, N.; Renner, M.; Kirfel, J.; Steiner, S.; Huss, S.; et al. SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma. Oncogene 2014, 33, 5006–5016. [CrossRef] [PubMed]
15. Pretto, D.; Barco, R.; Rivera, J.; Neel, N.; Gustavson, M.D.; Eid, J.E. The synovial sarcoma translocation protein SYT-SSX2 recruits β-catenin to the nucleus and associates with it in an active complex. Oncogene 2006, 25, 3661–3669. [CrossRef] [PubMed]
16. Cironi, L.; Petricevic, T.; Fernandes Vieira, V.; Provero, P.; Fusco, C.; Cornaz, S.; Fregni, G.; Letovanec, I.; Aguet, M.; Stamenkovic, I. The fusion protein SS18-SSX1 employs core Wnt pathway transcription factors to induce a partial Wnt signature in synovial sarcoma. Sci. Rep. 2016, 6, 22113. [CrossRef]
17. Barham, W.; Frump, A.L.; Sherrill, T.P.; Garcia, C.B.; Saito-Diaz, K.; VanSaun, M.N.; Fingleton, B.; Gleaves, L.; Orton, D.; Capecchi, M.R.; et al. Targeting the Wnt pathway in synovial sarcoma models. Cancer Discov. 2013, 3, 1286–1301. [CrossRef]
18. Shitashige, M.; Naishiro, Y.; Idogawa, M.; Honda, K.; Ono, M.; Hirohashi, S.; Yamada, T. Involvement of splicing factor-1 in β-catenin/T-cell factor-4-mediated gene transactivation and pre-mRNA splicing. Gastroenterology 2007, 132, 1039–1054. [CrossRef]
19. Shitashige, M.; Satow, R.; Jigami, T.; Aoki, K.; Honda, K.; Shibata, T.; Ono, M.; Hirohashi, S.; Yamada, T. Traf2- and Nck-interacting kinase is essential for Wnt signaling and colorectal cancer growth. Cancer Res. 2010, 70, 5024–5033. [CrossRef]
20. Masuda, M.; Sawa, M.; Yamada, T. Therapeutic targets in the Wnt signaling pathway: Feasibility of targeting TNIK in colorectal cancer. Pharmacol. Ther. 2015, 156, 1–9. [CrossRef]
21. Masuda,M.; Uno, Y.; Ohbayashi, N.; Ohata, H.; Mimata, A.; Kukimoto-Niino,M.; Moriyama, H.; Kashimoto, S.; Inoue, T.; Goto, N.; et al. TNIK inhibition abrogates colorectal cancer stemness. Nat. Commun. 2016, 7, 12586. [CrossRef] [PubMed]
22. Yamada, T.; Masuda, M. Emergence of TNIK inhibitors in cancer therapeutics. Cancer Sci. 2017, 108, 818–823. [CrossRef] [PubMed]
23. Knoepfler, P.S. Myc goes global: New tricks for an old oncogene. Cancer Res. 2007, 67, 5061–5063. [CrossRef] [PubMed]
24. He, T.C.; Sparks, A.B.; Rago, C.; Hermeking, H.; Zawel, L.; da Costa, L.T.; Morin, P.J.; Vogelstein, B.; Kinzler, K.W. Identification of c-MYC as a target of the APC pathway. Science 1998, 281, 1509–1512. [CrossRef]
25. Sansom, O.J.; Meniel, V.S.; Muncan, V.; Phesse, T.J.; Wilkins, J.A.; Reed, K.R.; Vass, J.K.; Athineos, D.; Clevers, H.; Clarke, A.R. Myc deletion rescues Apc deficiency in the small intestine. Nature 2007, 446, 676–679. [CrossRef]
26. Barrios, C.; Castresana, J.S.; Ruiz, J.; Kreicbergs, A. Amplification of the c-myc proto-oncogene in soft tissue sarcomas. Oncology 1994, 51, 13–17. [CrossRef]
27. Vlenterie, M.; Litière, S.; Rizzo, E.; Marréaud, S.; Judson, I.; Gelderblom, H.; Le Cesne, A.; Wardelmann, E.; Messiou, C.; Gronchi, A.; et al. Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity. Eur. J. Cancer 2016, 58, 62–72. [CrossRef]
28. van der Graaf, W.T.; Blay, J.Y.; Chawla, S.P.; Kim, D.W.; Bui-Nguyen, B.; Casali, P.G.; Schöffski, P.; Aglietta, M.; Staddon, A.P.; Beppu, Y.; et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012, 379, 1879–1886. [CrossRef]
29. Lee, A.T.J.; Jones, R.L.; Huang, P.H. Pazopanib in advanced soft tissue sarcomas. Signal Transduct. Target. Ther. 2019, 4, 16. [CrossRef]
30. Nakamura, T.; Matsumine, A.; Kawai, A.; Araki, N.; Goto, T.; Yonemoto, T.; Sugiura, H.; Nishida, Y.; Hiraga, H.; Honoki, K.; et al. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study. Cancer 2016, 122, 1408–1416. [CrossRef]
31. Robbins, P.F.; Morgan, R.A.; Feldman, S.A.; Yang, J.C.; Sherry, R.M.; Dudley, M.E.; Wunderlich, J.R.; Nahvi, A.V.; Helman, L.J.; Mackall, C.L.; et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 2011, 29, 917–924. [CrossRef] [PubMed]
32. D’Angelo, S.P.; Melchiori, L.; Merchant, M.S.; Bernstein, D.; Glod, J.; Kaplan, R.; Grupp, S.; Tap, W.D.; Chagin, K.; Binder, G.K.; et al. Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 (c259)T Cells in Synovial Sarcoma. Cancer Discov. 2018, 8, 944–957. [CrossRef] [PubMed]
33. Nagayama, S.; Fukukawa, C.; Katagiri, T.; Okamoto, T.; Aoyama, T.; Oyaizu, N.; Imamura, M.; Toguchida, J.; Nakamura, Y. Therapeutic potential of antibodies against FZD 10, a cell-surface protein, for synovial sarcomas. Oncogene 2005, 24, 6201–6212. [CrossRef] [PubMed]
34. Li, H.K.; Sugyo, A.; Tsuji, A.B.; Morokoshi, Y.; Minegishi, K.; Nagatsu, K.; Kanda, H.; Harada, Y.; Nagayama, S.; Katagiri, T.; et al. α-particle therapy for synovial sarcoma in the mouse using an astatine-211-labeled antibody against frizzled homolog 10. Cancer Sci. 2018, 109, 2302–2309. [CrossRef]
35. Giraudet, A.L.; Cassier, P.A.; Iwao-Fukukawa, C.; Garin, G.; Badel, J.N.; Kryza, D.; Chabaud, S.; Gilles-Afchain, L.; Clapisson, G.; Desuzinges, C.; et al. A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. BMC Cancer 2018, 18, 646. [CrossRef]
36. Kadoch, C.; Crabtree, G.R. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell 2013, 153, 71–85. [CrossRef]
37. Middeljans, E.; Wan, X.; Jansen, P.W.; Sharma, V.; Stunnenberg, H.G.; Logie, C. SS18 together with animal-specific factors defines human BAF-type SWI/SNF complexes. PLoS ONE 2012, 7, e33834. [CrossRef]
38. Mora-Blanco, E.L.; Mishina, Y.; Tillman, E.J.; Cho, Y.J.; Thom, C.S.; Pomeroy, S.L.; Shao, W.; Roberts, C.W. Activation of β-catenin/TCF targets following loss of the tumor suppressor SNF5. Oncogene 2014, 33, 933–938. [CrossRef]
39. Barrott, J.J.; Illum, B.E.; Jin, H.; Zhu, J.F.; Mosbruger, T.; Monument, M.J.; Smith-Fry, K.; Cable, M.G.; Wang, Y.; Grossmann, A.H.; et al. β-Catenin stabilization enhances SS18-SSX2-driven synovial sarcomagenesis and blocks the mesenchymal to epithelial transition. Oncotarget 2015, 6, 22758–22766. [CrossRef]
40. Mahmoudi, T.; Li, V.S.; Ng, S.S.; Taouatas, N.; Vries, R.G.; Mohammed, S.; Heck, A.J.; Clevers, H. The kinase TNIK is an essential activator of Wnt target genes. EMBO J. 2009, 28, 3329–3340. [CrossRef]
41. Meichle, A.; Philipp, A.; Eilers, M. The functions of Myc proteins. Biochim. Biophys. Acta 1992, 1114, 129–146. [CrossRef]
42. Levens, D. Cellular MYCro economics: Balancing MYC function with MYC expression. Cold Spring Harb. Perspect. Med. 2013, 3, a014233. [CrossRef]
43. Riou, G.; Barrois, M.; Le, M.G.; George, M.; Le Doussal, V.; Haie, C. C-myc proto-oncogene expression and prognosis in early carcinoma of the uterine cervix. Lancet 1987, 1, 761–763. [CrossRef]
44. Garte, S.J. The c-myc oncogene in tumor progression. Crit. Rev. Oncog. 1993, 4, 435–449.
45. Shen, J.; Scotlandi, K.; Baldini, N.; Manara, M.C.; Benini, S.; Cerisano, V.; Picci, P.; Serra, M. Prognostic significance of nuclear accumulation of c-myc and mdm2 proteins in synovial sarcoma of the extremities. Oncology 2000, 58, 253–260. [CrossRef] [PubMed]
46. Nakayama, R.; Mitani, S.; Nakagawa, T.; Hasegawa, T.; Kawai, A.; Morioka, H.; Yabe, H.; Toyama, Y.; Ogose, A.; Toguchida, J.; et al. Gene expression profiling of synovial sarcoma: Distinct signature of poorly differentiated type. Am. J. Surg. Pathol. 2010, 34, 1599–1607. [CrossRef] [PubMed]
47. Machen, S.K.; Easley, K.A.; Goldblum, J.R. Synovial sarcoma of the extremities: A clinicopathologic study of 34 cases, including semi-quantitative analysis of spindled, epithelial, and poorly differentiated areas. Am. J. Surg. Pathol. 1999, 23, 268–275. [CrossRef]
48. Naka, N.; Takenaka, S.; Araki, N.; Miwa, T.; Hashimoto, N.; Yoshioka, K.; Joyama, S.; Hamada, K.; Tsukamoto, Y.; Tomita, Y.; et al. Synovial sarcoma is a stem cell malignancy. Stem Cells 2010, 28, 1119–1131. [CrossRef]
49. Kawai, A.; Naito, N.; Yoshida, A.; Morimoto, Y.; Ouchida, M.; Shimizu, K.; Beppu, Y. Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1. Cancer Lett. 2004, 204, 105–113. [CrossRef]
50. Masuda, M.; Chen, W.Y.; Miyanaga, A.; Nakamura, Y.; Kawasaki, K.; Sakuma, T.; Ono, M.; Chen, C.L.; Honda, K.; Yamada, T. Alternative mammalian target of rapamycin (mTOR) signal activation in sorafenibresistant hepatocellular carcinoma cells revealed by array-based pathway profiling. Mol. Cell. Proteom. 2014, 13, 1429–1438. [CrossRef]
51. Schneider, C.A.; Rasband, W.S.; Eliceiri, K.W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 2012, 9, 671–675. [CrossRef] [PubMed]
52. Ito, J.; Asano, N.; Kawai, A.; Yoshida, A. The diagnostic utility of reduced immunohistochemical expression of SMARCB1 in synovial sarcomas: A validation study. Hum. Pathol. 2016, 47, 32–37. [CrossRef] [PubMed]
53. Amary, M.F.; Berisha, F.; Bernardi Fdel, C.; Herbert, A.; James, M.; Reis-Filho, J.S.; Fisher, C.; Nicholson, A.G.; Tirabosco, R.; Diss, T.C.; et al. Detection of SS18-SSX fusion transcripts in formalin-fixed paraffin-embedded neoplasms: Analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcoma. Mod. Pathol. 2007, 20, 482–496. [CrossRef] [PubMed]
54. Miyanaga, A.; Honda, K.; Tsuta, K.; Masuda, M.; Yamaguchi, U.; Fujii, G.; Miyamoto, A.; Shinagawa, S.; Miura, N.; Tsuda, H.; et al. Diagnostic and prognostic significance of the alternatively spliced ACTN4 variant in high-grade neuroendocrine pulmonary tumours. Ann. Oncol. 2013, 24, 84–90. [CrossRef]